Company research / ERNA

Ernexa Therapeutics Inc. (ERNA)

Also trades as ERNAW. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

CIK 0000748592 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Key ratios (year ended 2025-12-31)

-586.6%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-15

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-20, first reflected in a filing dated 2022-11-14; 1-for-15, first reflected in a filing dated 2025-08-13. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenuen/an/a$582.0K$68.0K$0n/a$5.80M$19.81M$23.34M$21.27M$22.31M
Cost of Revenuen/an/a$96.0K$236.0K$0n/an/an/an/an/an/a
Gross Profitn/an/a$486.0K-$168.0K$0n/an/an/an/an/an/a
R&D Expense$6.42M$4.16M$4.60M$5.92M$10.39M$12.71M$3.95Mn/an/an/an/a
Operating Income-$13.78M-$9.32M-$15.67M-$21.14M-$33.22M-$113.73M-$7.25M-$1.76M$203.0K-$1.40M-$2.28M
Depreciation & Amortization$47.0K$65.0K$139.0K$84.0K$161.0K$117.0K$98.0K$2.88M$2.76M$2.32M$2.89M
EBITDA-$13.73M-$9.25M-$15.54M-$21.05M-$33.06M-$113.61M-$7.15M$1.11M$2.97M$915.0K$609.0K
Net Income-$12.26M-$14.08M-$44.54M-$21.67M-$24.58M-$122.55M-$7.29M-$2.05M-$259.0K-$1.08M-$2.92M
EPS (Diluted)n/a-$2.24-$48.96-$4.08-$8.06-$56.61-$0.41n/an/an/an/a
Total Assets$6.32M$5.83M$5.27M$49.13M$22.28M$31.52M$12.91M$14.12M$14.86M$16.57M$16.70M
Total Liabilities$3.12M$3.43M$3.57M$46.90M$10.17M$6.02M$5.25M$9.03M$7.95M$11.03M$12.63M
Long-Term Debtn/an/an/an/an/an/an/an/a$3.75M$5.12M$8.11M
Shareholders' Equity$3.20M$2.40M$1.70M$2.23M$12.11M$25.50M$7.66M$5.09M$6.92M$5.54M$4.07M
Cash & Equivalentsn/an/a$1.73M$7.58M$11.45M$16.98M$777.0K$3.21M$2.54M$3.38M$5.69M
Operating Cash Flow-$8.84M-$7.02M-$15.84M-$20.41M-$20.98M-$23.49M-$8.10M$2.74M$1.36M$549.0K$23.0K
Capital Expendituresn/a$37.0K$369.0K$19.0K$297.0K$154.0K$39.0K$128.0K$648.0K$728.0K$427.0K
Free Cash Flown/a-$7.05M-$16.20M-$20.43M-$21.27M-$23.64M-$8.14M$2.62M$717.0K-$179.0K-$404.0K
Shares Outstanding1.17M7.85M3.43M5.41M5.13M2.60M2.97M2.90M2.88M2.52M2.26M
Weighted Average Diluted Sharesn/a6.31M910.0K5.31M3.05M2.17M17.59Mn/an/an/an/a
EPS (Basic)n/a-$2.24-$48.96-$4.08-$8.06-$56.61-$0.41n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView